Anish Patel Sells 21,700 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 21,700 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total value of $524,706.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Anish Patel also recently made the following trade(s):

• On Friday, October 18th, Anish Patel sold 716 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $21,480.00.

Enliven Therapeutics Price Performance

ELVN opened at $21.74 on Friday. The business has a 50 day simple moving average of $24.54 and a 200-day simple moving average of $24.41. The stock has a market capitalization of $1.06 billion, a P/E ratio of -11.44 and a beta of 1.04. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds have recently bought and sold shares of the company. Quest Partners LLC increased its stake in Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Enliven Therapeutics by 12.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company’s stock valued at $668,000 after purchasing an additional 2,944 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Enliven Therapeutics by 25.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after purchasing an additional 3,518 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Enliven Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after purchasing an additional 3,559 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after purchasing an additional 8,540 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ELVN has been the subject of a number of recent research reports. Robert W. Baird increased their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. BTIG Research assumed coverage on Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.